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Abstract
Background: Multimorbid patients in nursing homes are prescribed long lists of medication, often without
sufficient clinical evaluations beforehand. This results in poor clinical effects of the prescribed medication and
significant side-effects, especially in patients with impaired cognition. The aim of this paper is to describe the
process, content and implementation of a clinical medication review encompassing clinical testing and collegial
support to prescribers.
Methods: The implementation process of a novel approach to medication review in nursing homes was logged
thoroughly by structured staff feedback. Staff experienced promotors and barriers to implementation also were
collected. The study was part of a cluster randomized controlled trial, in which 36 long-term care units received the
COSMOS intervention. Nurses and physicians randomized to the intervention group participated in educational
programs, training in clinical evaluation of the patients, and interprofessional medication review with collegial
mentoring.
Results: The intervention group contained 297 patients from 36 nursing home units. There were 105 staff
attendees for the education program. The units were served by 21 different physicians. Clinical medication reviews
were performed in all units and all patients were assessed prior to the medication reviews. Of the 240 patients with
a logged intervention process, 220 (92%) underwent a medication review. The intervention generated enthusiasm
and improved communication among nursing staff and between nursing staff and physicians. The interprofessional
discussions helped to facilitate difficult decisions pertaining to treatment levels. Reported barriers were lack of time,
low engagement of all nursing staff and physicians, and ethical dilemmas.
Conclusions: Clinical medication reviews were implemented for almost all patients, and every patient was
systematically assessed prior to the medication review. The physicians perceived collegial mentoring as an asset,
learning from each other facilitated decision making in terms of difficult aspects of prescribing. Knowledge about
barriers and promotors can improve implementation of similar interventions in other nursing homes.
Trial registration: Clinicaltrials.gov (NCT02238652). Registered July 7th 2014.
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Background
Nursing home patients are old and fragile, and over 80%
have dementia [1]. Multimorbidity is common in old
age, and cardiovascular diseases, stroke, cancer, and psy-
chiatric disorders often co-occur [2, 3]. A consequence
of multimorbidity is polypharmacy, affecting most nurs-
ing home patients, who on average use eight different
drugs every day, and two on demand [4]. The altered
pharmacokinetics and pharmacodynamics of the aged
body increase susceptibility to adverse events from drugs
[5]. A study by Soraas et al. (2014) found that the use of
eight or more drugs significantly increased the risk of
drug-drug interactions [6], which in turn leads to falls,
cognitive decline, medication-related problems, and even
increased mortality [7–10].
In nursing homes, physicians frequently prescribe
drugs without a proper clinical evaluation of the patient
[11]. Dementia reduces the patient’s ability to report ef-
fects and side effects of the treatment and depend on a
proxy-rater who has known the patient over time to
conduct a medical evaluation. It has been suggested that
a systematic review of medications might be a procedure
that will help ensure safe and appropriate medical treat-
ment. Randomized controlled trials in nursing homes
have been used to test medication reviews including: ex-
pert advice, the use of explicit prescribing lists, and
multidisciplinary teams with the general practitioner
(GP) involved [12–14]. They all demonstrated a reduc-
tion in the number of drugs without a detrimental effect
on the patient’s health. Other approaches have been
tested to improve drug prescribing by involving: a
pharmacist, electronic prescribing aides, and the use of
explicit prescribing criteria [15–17]. The interventions
often comprise of multiple components, require new
knowledge and involve different professions; it has been
demonstrated that these elements impede implementa-
tion [18].
To ensure that complex interventions are successful
and sustainable over time, different approaches have to
be combined, and the implementation process must be
planned and described in detail. Yet, multicomponent
intervention studies have fallen short in reporting their
implementation strategies and evaluation there-of [16].
Consequently, lack of efficacy may be caused by poor
implementation, the ineffectiveness of the method or a
combination of the two. We believe that we can improve
prescribing and the medication review procedure in
nursing homes by incorporating clinical assessment
using tools validated for people with dementia, and by
testing to ascertain whether the intervention was carried
out successfully.
In this paper, we describe a novel implementation
strategy for an interprofessional medication review. It is
based on systematic clinical evaluation of the patient
and collegial mentoring of the nursing home team. We
describe the process of implementation and report the
findings for the following research questions:
1. How did nursing home staff receive the
intervention?
2. To what degree was the medication review
implemented successfully?
3. What are the barriers and facilitators for




The medication review was a part of the COSMOS study,
a 9-month multicenter, cluster randomized controlled trial
[19]. The trial used a multicomponent intervention, con-
sisting of five elements represented by the acronym COS-
MOS: COmmunication, Systematic pain assessment and
treatment, Medication review, Organization of activities,
and Safety. We have previously described the study proto-
col in detail [19], and the main outcomes [20]; the trial is
registered at clinicaltrials.gov (NCT02238652).
For this study, we include data from the 36 Norwegian
nursing home units that received the COSMOS inter-
vention, covering 297 patients. The recruited nursing
homes were located in small and large municipalities, in
different geographical locations, and from more or less
prosperous municipalities. We included long-term care
units and specialized dementia wards with unit capacity
varying from eight to 28 patients per unit. All patients
living in or moving into the units during the first two
months of the trial were eligible for inclusion if they had
a minimum stay of two weeks before the first assess-
ment. We excluded patients under 65 years of age, those
with schizophrenia, and patients deemed by the nursing
home physician to have less than six months to live. In
general, medical treatment in Norwegian nursing homes
is provided by physicians (mostly GPs) working one to
five days a week in the nursing home. The proposed
standard of care by the Norwegian Medical Association
for Norwegian long-term care patients are 90 patients
per full time physician [21].
Implementation of the medication review
The implementation consisted of six steps demonstrated
in Fig. 1.
Step 1: Initially, nursing home managers, registered
nurses, licensed practical nurses, unit managers, physi-
cians, and pharmacists from the intervention nursing
homes were invited to participate in a standardized edu-
cation program (Fig. 1.1). The program started with a
two-day seminar held by the researchers (BSH and EF).
One prerequisite was that at least two nurses (named
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“COSMOS ambassadors”) from each nursing home unit,
who had regular patient contact, had to participate in the
program. The education consisted of four hours lecturing,
role-playing, and problem-solving discussions on a)
Pharmacodynamics, pharmacokinetics, multimorbidity, and
clinical challenges; b) Importance of systematic clinical as-
sessment, documentation and follow-up; c) Unnecessary
drug use, and drugs with relevant adverse or anticholinergic
effects; d) Drug-drug interactions; e) Training the unit’s
staff and practical information about the medication review.
Fig. 1 The medication review process: 1: Researchers educated nursing home staff (“COSMOS ambassadors”), physicians, and nursing home
leaders in safe use of drugs and the medication review intervention. 2: The COSMOS ambassadors used the lessons from the education to train
the other staff in their units. 3: The researchers trained the nursing home staff in assessing the patients’ pain, neuropsychiatric symptoms,
cognition, daily function, and quality of life. 4: Multidisciplinary medication reviews with the researchers, nurses, and nursing home physician were
performed in each unit. The researcher gave collegial mentoring for the other participants. The results from the clinical assessments were used in
evaluation of the prescriptions for each patient. 5: After two months, the nursing home staff was gathered for a midway evaluation to discuss
promotors and barriers towards the implementation among themselves and with the researchers. 6: During the whole study period, the
researchers regularly called the COSMOS ambassadors to follow up on the implementation. The researchers gave advice on how to overcome
barriers, and collected practical tips from the COSMOS ambassadors that could be spread to other units
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The content of the education program was based on the
Norwegian guidelines for medication review [22], the Nor-
wegian Patient Safety Campaign [23], and literature re-
views on medication reviews in nursing homes [16, 17,
24–27]. The drug recommendations were based on the
Screening Tool of Older Persons Potentially Inappropriate
Prescriptions/Screening Tool to alert Doctors to Right
Treatment (START/STOPP) 2 criteria [28], and the Nor-
wegian Medicines Agency’s checklist for medication re-
views [29]. In addition, we adapted the anticholinergic
drug list developed by Duran et al., to drugs available on
the Norwegian market [30].
Step 2: After the initial 2-day seminar, the COSMOS
ambassadors were responsible for training the rest of the
unit’s staff in short session of about 10–20 min each
(Fig. 1.2). We encouraged them to adapt the procedure
to their local routines but made suggestions as to how
they could organize the training. For instance, we ad-
vised the ambassadors to offer training during lunch
and/or report several times a week to enable all nursing
staff members to participate. This train-the-trainer ap-
proach was employed to ensure that the medication re-
view implementation was sustainable, through involving
the entire nursing home unit [31].
Step 3: Researchers trained the nursing home staff in
assessing the patient’s pain, neuropsychiatric symptoms,
cognition, daily function, and quality of life. At the start
of the study, each patient was assessed using a range of
instruments developed and validated for use in elderly
patients and persons with dementia (Fig. 1.3, Table 1).
To ensure the quality of the assessments, at least two
registered nurses or licensed practical nurses underwent
four hours of individual training in the use and inter-
pretation of the instruments. The session was conducted
in the patients’ units with practical bedside mentoring;
for instance, the use of MOBID-2 was demonstrated
during the morning care of at least two patients.
Step 4: Medication reviews were performed by the nurs-
ing home physician together with the nurses and the re-
searchers (BSH: anaesthesiologist, nursing home and
palliative care physician; CG: physician), who provided col-
legial mentoring. The reviews were based on the results
from the clinical assessments. We used these results to
evaluate the necessity of the prescriptions for each patient
(Fig. 1.4). The COSMOS guidelines instructed that all pa-
tients should have a medication review at least biannually,
upon discharge from hospital and when their medical con-
dition changed. Each patient’s general condition, prescrip-
tions, and test results were discussed in detail. The drugs
were assessed, individually and overall, in terms of all the
patient’s conditions and life expectancy. For instance, if a
patient scored 4 on the Cornell Scale for Depression in
Table 1 Instruments used in assessment of patient prior to medication review
Short name Range Interpretation
Cognition
MMSE 0–30 The patient is asked 30 questions, scored correct (1) or wrong (0). Lower scores indicates lower cognitive function [47]. Normal
cognition was defined as: 26–30, mild dementia: 21–25, moderate dementia 11–20, severe dementia < 11 [48].
FASTa 1–7 Staging cognitive function, normal to severe dementia [49]. Normal cognition was scored as 1–2, 3–4 mild dementia, 5:
moderate dementia, and 6–7 severe dementia.
Neuropsychiatric symptoms
NPI-NHa 0–144 12 individual items: delusions, hallucination, agitation, depression, anxiety, euphoria, apathy, disinhibition, irritability, aberrant
motor behaviour, night-time behaviour, and eating disturbances. Each item is scored by frequency (“absent” to “daily”; 0–4),
and intensity for the patient (“mild” to “severe”; 1–3) these scores are multiplied to a sum score of 0–12 for each item and
summed to give a total score [33, 50].
CMAIa 29–203 29 items with agitated behaviors (scored by frequency: “never” to “multiple times an hour”; 1–7) [51]. Agitation was
defined as ≥39.
CSDDa 0–38 19 items on depressive behaviour (“absent” to “severe”; 0–2) [32]. Depression was defined as ≥8.
Pain
MOBID-2a 0–10 Pain intensity during five standardized, guided movements, and five domains related to internal organs, head and skin during
the last week, each item is scored 0 to 10 (“no pain” to “worst imaginable pain”). A total pain score is based on the worst pain
experienced. A score of ≥3 signifies a need for pain treatment [52, 53]
Activities of daily living
PSMSa 0–30 6 items of toileting, feeding, dressing, grooming, physical ambulation, and showering are scored whether the patient are able
to do the activity or unable (0–5), higher scores indicate more dependency [54].
Quality of life
QUALIDa 11–55 11 items on patient behaviour rated on severeness; 1 to 5. Lower score indicates higher quality of life [55].
aProxy-rated instrument. CMAI Cohen-Mansfield Agitation Inventory, CSDD Cornell Scale for Depression in Dementia, FAST Functional Assessment Staging, MMSE
Mini Mental State Examination, MOBID 2 Mobilization-Observation-Behaviour-Intensity-Dementia 2 Pain Scale, NPI-NH Neuropsychiatric Inventory- nursing home
version, QUALID quality of life in late-stage dementia
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Dementia (CSDD) [32], and the Neuropsychiatric Inven-
tory- nursing home version (NPI-NH) [33] item on depres-
sion was 4, both indicating no depression, and the patient
was prescribed an antidepressant, we discussed whether the
medication could be paused, or if there were reasons for
continued use. The responsible physician executed the
changes he or she saw fit based on the discussions. All
changes in drugs were documented in the electronic
patient record. The nursing staff re-assessed the pa-
tients` conditions after changes in drug treatment,
and the physicians re-instated the drug if deemed ne-
cessary. Table 2 shows each participant’s responsibil-
ities regarding the medication review.
Step 5: After two months, nursing home staff was
gathered for a midway evaluation to discuss promotors
and barriers towards the implementation with the re-
searchers. This was done by structured questions to each
unit. They were asked to state three things they per-
ceived they had succeeded with in the study, two things
they had performed to some degree but still had
some issues with, and one thing they had not per-
formed at all or found difficult. These experiences
were discussed in the group, and gave the staff the
possibility to share experiences and learn from each
other across the units (Fig. 1.5).
Step 6: COSMOS ambassadors were supported regu-
larly (twice a month) by telephone contact (Fig. 1.6). Re-
searchers gave advice on how to overcome barriers, and
shared practical tips from the COSMOS ambassadors
that could be spread to other units. The researchers
counseled the nursing home staff on how to discuss
medication changes with patients (if possible) and their
relatives, who were informed about the medication re-
view in advance. We recommended that if a drug was
to be stopped, the physician and nurse should use the
term “pause”. This ensured that the patient had to be
reevaluated after the cessation and patient and rela-
tives were less likely to interpret the change as a de-
nial of treatment.
Data collection and analyses
Patients were recruited and included in the study from
August 1st 2014 through March 15th 2015. Patients
were followed for four months, and the last follow up
data were collected June 19th 2015. Data on the patients’
medical information and information on drug prescrip-
tions were extracted from the patient’s medical record.
Ongoing drug prescriptions were coded according to the
fourth level of the Anatomical Chemical Therapeutic
(ATC) Index [34]. Psychotropic drugs included the
groups for antidepressants, antipsychotics, anxiolytics,
hypnotics, and anti-dementia drugs. A questionaire
about unit size and staffing was distributed to all unit
managers. All attending physicians filled in another
questionnaire to provide data on their gender, spesializa-
tion, employment, and number of patients they served.
Data on implementation was gathered using a “patient
log” in which the primary nurse could document the im-
plementation progress of every patient. The following five
questions were answered (yes/no/not relevant): 1. Has a
medication review been conducted? 2. Are all drug indica-
tions recorded? 3. Are changes in patient’s health docu-
mented? 4. Have any drugs been re-instated after
withdrawal? 5. Is the patient (if mentally capable) and/or
relatives informed about changes in the medication? In
addition, the nurse had the option of writing comments.
The researchers collected the logs at the end of the
month-four data collection. Perceived barriers and pro-
moters to the implementation were collected from the
structured questions at the midway evaluation, we also
gathered the remarks from the patient logs, as well as
through feedback given to the researchers during medica-
tion reviews. These data were gathered in a database.
Analyses
Demographics and clinical characteristics for the base-
line population were presented with means and standard
deviation (SD) or frequencies and percentages, as appro-
priate. All analyses were performed in IBM SPSS version
23, (Armork, NY). “To gain insight into the diversity of
barriers and promotors, we chose a qualitative approach.
We used a simple thematic analysis as described by N
Mays and C Pope [35] to systematically examine these
issues, to be able to identify promotors and barriers.
Two researchers (CG and RLSK) read the transcribed
feedback independently, and systematically searched for
Table 2 Responsibilities for the participants concerning the medication reviews
Participant Responsibilities
Physician Order relevant blood tests before the medication review. Already existing blood test results could be used if they were not older than
two weeks. Medical decision-making, including choice of drug and dose.
Nurse Prior to the meeting use www.interaksjoner.no [56] to identify potential drug-drug interactions for each patient. Report the patient’s
condition and complaints, and close observation and follow-up after changes in treatment. Information to patients, relatives, and nurs-
ing staff about changes.
Researchers Plan the meeting and compile the results from the baseline assessment of the patients on a spreadsheet. Guide the interprofessional
team through the medication review. Provide collegial mentoring and updated knowledge. Give general information on the physician’s
prescribing practice, such as average number of regular and on demand prescriptions, in comparison to national numbers
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recurring themes of interest. We thematically coded the
“main messages”, at first using the participants language,
then gradually refining the codes and developing clearer
categories through an iterative process of re-reading and
discussion [35].”
Results
Twenty of the 36 intervention units (56%) reported hav-
ing had a focus on medication reviews in the three years
preceding the intervention. Six units had participated in
the Norwegian Patient Safety Campaign on improving
prescribing in nursing homes [23], five had been a part
of a research project focusing on medication review, and
eight had a local focus on medication reviews. No phar-
macists attended the medication reviews or the educa-
tion, mostly because the units did not have any
pharmacists on staff (Table 3).
Twenty-one physicians had the medical responsibility
for the nursing home units (Table 3). Seven physicians
(33%) were full-time nursing home physicians and 14
(67%) were GPs with visiting hours at the nursing home.
Thirteen had a specialization, 12 of which were in family
medicine, and one in internal medicine. The nursing
staff in the units consisted of registered nurses, licensed
practical nurses, and staff without training. In 30 (45%)
units, most staff were hired in 75–100% of full-time
equivalent positions; in 24 units (36%), most staff held
50–75% of full-time equivalent positions.
The patients had a mean age of 87 (SD = 7.7) years,
73% were female, and they had a mean of 4 (SD = 3.3)
registered diagnoses each. During the four months of
the study, 33 patients died and 14 moved to another in-
stitution. All participants used a mean of 7.6 (SD = 3.8)
drugs each day, ranging from 0 to 19, and had on aver-
age 3.4 (SD = 2.3) on demand prescriptions, ranging
from 0 to 17. The most frequent regular drug groups
were: laxatives (N = 172, 58%), antithrombotic agents,
(N = 155, 52%), acetaminophen (N = 136, 46%), antide-
pressants (N = 118, 40%), and high ceiling diuretics (N =
95, 32%). The most frequent drugs on demand were
acetaminophen (N = 147, 50%), anxiolytics (N = 134,
45%), opioids (N = 106, 36%), hypnotics (N = 82, 28%),
and laxatives (N = 79, 27%).
Education of nursing home staff
The education program was attended by 105 nursing
staff. All units in the intervention group participated and
all units sent the required two ambassadors, the average
number was three participants per unit. The attendees
were mainly two registered nurses and a unit manager
or a licensed practical nurse for each unit. Seven of the
21 physicians attended the education program. The
non-attending physicians cited limited time and lack of
relevance as reasons for not attending. The same num-
ber of people attended the midway evaluations as the
education program. These meetings had no management
level staff or physicians present, but more regular nurs-
ing staff participated.
The training materials were clearly visible in all units
during visits from the researchers. Ten units asked for
an additional supply of flash cards because of their
popularity; seven units wanted extra training loose-leaf
binders.
Interprofessional medication review based on collegial
mentoring
All units conducted the medication review. Some physi-
cians had responsibility for several units and thus the
visits were coordinated so that they could be performed
in one appointment. Six units took the opportunity to
Table 3 Experience, education and workload in health professionals in the intervention group
Nursing home units in nursing home, N 36 units in 18 NH
Staffing, number of patients per nursing staffa (range) Daytime 3.2 (1.6–4.0)
Evening 4.7 (2.3–6.0)
Nighttime 13.0 (4.0–30.3)
COSMOS ambassadors with direct patient contact, N (N per cluster) 73 (2.0)
Registered nurses, N (%) 44 (61%)
Licensed practical nurses, N (%) 9 (12%)
Unknown education 19 (27%)
Physicians 21
Age in years, mean (SD) 48 (12.9)
Female, N (%) 8 (38%)
Mean number of patients in the study, per physician, mean (range) 22 (8–28)
Minutes per patient per week, mean (range) 20 (8–42)
aNursing staff: Registered nurses, licensed practical nurses, and uneducated staff
N Number, NH nursing homes, SD Standard deviation
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have additional medication reviews. All patients were
assessed prior to the scheduled medication review. The
nursing home physician and a nurse from the unit
attended each medication review; in addition, an extra
nurse or the unit manager attended about half of these
medication reviews. Using the COSMOS method, the
group spent on average 1.5 h (range 1 to 2 h) performing
medication reviews for eight patients. The first few patient
cases were discussed extensively, while decisions were eas-
ier to make with the subsequent cases, because similar is-
sues had already been discussed in previous cases.
Implementation process
All units used the patient logs, though 57 patients (19%)
were missing log entries over four months, attributable
to either death or being moved from the unit during the
intervention period (77%). As the total number of pa-
tients remaining in the study declined, the total number
of patients changed throughout registration. For the first
four weeks, the log was filled in for 211/294 (73%). The
completion rates for week 8, 12, and 16 were: 206/288
(71%), 140/276 (51%), and 198/271 (73%), respectively.
Of the patients with at least one entry in the logs, 220
(92%) had received a medication review. Medication in-
dications were recorded for 200 (83%) of the patients.
For 184 (77%) of the patients, either the patient himself/
herself or relatives were informed about changes in
drugs, and for 34 (14%) patients the nurse filling in the
log did not know whether this information was given. In
72 (30%) of the cases, a drug was reinstated after a
pause, and changes in health were documented in 204
(77%) of the patients (Table 4).
Barriers and promotors for good implementation
Healthcare staff reported potential barriers and promotors
for the implementation process during the medication re-
view and the midway evaluation (Table 5). The staff wel-
comed this approach, which they felt, created an arena for
learning, engagement and further development. One par-
ticipant also expressed this enthusiastically: I want to run
back to my nursing home unit and look over all the medi-
cation charts right away!
The implementation of the systematic clinical evalu-
ation by means of validated assessment instruments was
straightforward for most of the nursing staff. Meanwhile,
some units struggled with new or unfamiliar instruments
and some of the nurses were less interested or did not
regard the evaluation of the patient as their responsibil-
ity. Licensed practical nurses also felt less competent to
evaluate changes in patient health or to communicate
with the relatives in connection with the medical
changes. The introduction of the word “pause” was
regarded as a relief because it was easier for the relatives
and the other staff in the unit to accept a pause rather
than discontinuation of a drug. Practical difficulties
where mainly related to the use of multi-dose dispensed
drugs when several medications were changed at the
same time. The doctors also had varying degrees of
knowledge about the electronic patient record and some
found it difficult to alter prescriptions. Thus, they
depended on nurses to be present at the medication re-
view and to follow up and document the changes in the
system. Despite the fact that most GPs did not attend
the seminar at baseline, the collegial monitoring was
seen as positive and they were receptive to the medica-
tion review with the researchers. They appreciated the
discussions with the nurses and researchers in the inter-
professional setting. Not surprisingly, there was not al-
ways agreement in their professional opinions but
observations made by the nurses in advance or related
to scorings by the clinical assessments, influenced the
prescribing routines positively and improved the com-
munication between the staff members.
Several physicians suggested that the collegial support
from the researchers and the interprofessional discussion
provided help in the decision-making processes, as one
colleague commented: It is never easy to find the correct
timing for deprescribing, for instance, anticoagulants to
prevent a stroke. It is an ethical issue, you know. Notably,
these judgments were often related to drugs that were
Table 4 Feedback by patient logs
Whole period (N = 240)
Yes No Not applicable; don’t know
Question in patient logs N % N % N %
Had at least one medication review 220 92% 16 7% 3 1%
Indication on each drug 200 83% 36 15% 4 2%
Informed patient and/or relative about change 204 85% 9 4% 26 11%
Reinstated drug after pause 72 30% 141 59% 27 11%
Documented change in patient health 184 77% 20 8% 34 14%
The answers in the patient logs were coded accordingly: If there were one or more “yes” in the 16 weeks of registration, the answer was coded yes. If there were
one or more “no”, and no entries answered “yes”, we coded it as no. If there were one or more not applicable/don’t know, and no entries with yes or no, we
coded it as not applicable/don’t know. The table includes only patients with at least one entry (57 excluded). Due to missing data, the numbers do not add up
to 240
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initiated during a hospitalization, often a long time ago,
even when indications were no longer relevant.
Lack of time was a key barrier mentioned by all partici-
pants, including limited time for training, evaluation of the
patients, and proper documentation. Meanwhile, motivated
managers were able to initiate the medication review, des-
pite the time-barriers. One nurse said: Our boss encourages
us and has provided a schedule for all the training and ob-
servations we are supposed to do; she also checks whether
we have done it. To conclude, participants felt that the
intervention was needed and relevant. It granted knowledge
and highlighted problems that they all felt were present. In
addition, the relatives reported to the nurses that they were
pleased with this thorough approach.
Discussion
This study describes a new approach for systematic
medication review based on clinical assessment of the
patient and collegial mentoring of the physicians in Nor-
wegian nursing homes. The implementation of the inter-
vention was highly appreciated and well received by the
physicians and created enthusiasm among nursing staff.
The approach improved communication between the
health personnel, patients, and the relatives. After four
months, 92% of the patients had undergone a medica-
tion review, changes in the patients’ health were docu-
mented for 77% of the patients. Thirty percent of the
patients were put back on a deprescribed drug. Lack of
time was the most frequently reported barrier against
the intervention as well as difficulties in engaging every-
one in the unit. The systematic use of clinical assess-
ment tools before and after the medication review was
of key importance to the clinician because this facilitated
the optimizing of safe prescribing patterns.
To our knowledge, this is the first study that describes
the implementation strategy of collegial monitoring
combined with thorough clinical testing of nursing home
patients in connection with a medication review. Nurs-
ing home patients often suffer from neuropsychiatric
symptoms, and consequently, psychotropic drugs are
frequently prescribed [36]. To avoid unnecessary drug
use, and thus side effects and interactions, it is a pre-
requisite to assess relevant clinical symptoms before and
after treatment has been initiated. In an Australian
randomized controlled trial, Potter and colleagues in-
cluded 96 participants, who were systematically assessed
by two researchers [12]. During the medication review,
they were able to withdraw risk-modifying drugs, and to
some extent symptom-modifying drugs. However, they
did not report how neuropsychiatric symptoms were
assessed and re-assessed after optimizing the medication
lists. In the WHELD study, Ballard et al. focused on
antipsychotic drug use in connection with neuropsychi-
atric symptoms on 187 nursing home patients [37]. After
9 months, the intervention group reduced antipsychotic
drug use by 50% compared to the control group. The
antipsychotic review group experienced a worse out-
come of overall neuropsychiatric symptoms after the
procedure. Meanwhile, social interaction and exercise
proved to be essential to alleviate these symptoms. Both
studies describe complex interventions but the imple-
mentation strategies were not carried out as planned in
these settings. Furthermore, none of these studies in-
cluded the nursing home physician in the medication re-
views. In a different publication [38], we describe how
the COSMOS study showed significant reduction in use
of antihypertensive drugs in the intervention group com-
pared to the control group, without any lasting effect on
pulse or blood pressure.
It is of key importance to follow up and document
changes after the medication review. We found that
nearly 80% of the patients had changes in their health
documented after the medication review. We also found
that 30% had a drug reinstated after a pause. The study
by Potter et al. had 41% unsuccessful withdrawal rate
[12]. A Swedish study focusing on improving health
monitoring of nursing home patients reduced drug use
and increased documentation and follow-up [39].
The development, implementation and evaluation of
complex interventions as described by the Medical Re-
search Council guidance, UK, is challenging [40]. The
process depends on a range of possible outcomes, the
variability in the target population, and the number and
content of the elements in the intervention package.
Thus far, few trials have focused on the critical issue of
whether the implementation of a systematic medication
review is feasible in nursing homes or whether the staff
would be receptive to the intervention [16].
Table 5 Barriers and promotors for good implementation
Barriers Promoters
New and difficult clinical instruments Engagement
Lack of competence Arena for learning
Practical challenges with changing drug regimes Introducing a colleague to discuss difficult decisions with
Poor knowledge about electronic patient records The intervention was perceived as important and relevant
Lack of time Improved communication
Ethical dilemmas Pleased relatives
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Implementation studies allow for testing effectiveness of
an intervention and at the same time investigating the
implementation [41]. We found that the medication re-
views were implemented in all wards and almost all pa-
tients received a medication review. In contrast, in the
ARCHUS study from New Zealand, using education and
multidisciplinary teams, only 23% of the participants in
the intervention group were discussed during the team
meetings [42].
Promotors and barriers affect the implementation
process and depend on environmental factors, resources,
beliefs about consequences, and social and professional
roles [18]. In our study, time and available resources are
considered the greatest barriers to implementation in
clinical practice. However, some participants highlighted
the value of prioritizing an intervention they perceived
as being important, leading to increased knowledge
among the healthcare professionals. A systematic review
demonstrates that key factor for successful interventions
in nursing homes are the involvement of the stake-
holders and management-level healthcare professionals
and to enlist commitment to support nursing staff to
prioritize the intervention [43].
During the collegial mentoring, we encountered a
number of ethical dilemmas when drugs or doses
were changed or withdrawn. For instance, the depre-
scribing of anticoagulants or antibiotics often led to
discussions about possible consequences. Interestingly,
physicians tend to place more emphasis on actions
than on omissions, and guilt deriving from negative
consequences of an action is greater than guilt from
inaction [44]. We observed that the process may cre-
ate an arena for discussion and problem solving, and
that it may bolster the communication between the
participants. The roles of each participant in the
medication review process were clearly defined. This
might explain the feeling of improved communication
between all the involved parties, leaning a voice in
the interprofessional discussion to everybody.
In our study, we met nursing home staff members
who were eager to expand their knowledge. Although
physicians were often more difficult to include, commit-
ment among staff members has been highlighted as a
key factor for successful implementation, whereas a high
turnover rate in personnel appears to weaken participa-
tion and implementation [45]. Despite the fact that the
physician has the main responsibility for drug prescrip-
tion, physicians have routinely been ignored in studies
on medication reviews and only few studies include the
attending physician [15–17, 24–26]. Meanwhile, in other
countries, engaged pharmacists may assist in medication
review. This was not possible in our study, because
in-house pharmacists are seldom available in Norwegian
nursing homes.
The main strengths of this study are the comprehensive
sample size, the variety of units, and the active involvement
of the patients’ physicians and nurses. However, this paper
also has some limitations. It was not in the scope of the
present paper to report patient-related health outcomes, or
to evaluate changes in quality of life, as called for by Alldred
et al. [15]. Our focus was to investigate the process in which
the intervention was implemented as requested, which is
often left out in other studies [16]. However, effect of the
study has been reported elsewhere [20, 38]. The interven-
tion might seem complex and time consuming, especially
the assessment of patients’ pain and neuropsychiatric symp-
toms. Since these symptoms are common and drugs to
treat these conditions are frequently prescribed, these as-
sessments are essential. The use of two dedicated re-
searchers in medication reviews is not feasible in clinical
practice. On the other hand, we experienced during the
medication reviews that it was the collegial discussion the
physicians and nurses valued highly. We therefore suggest
that local collegial networks might facilitate medication re-
views. Unfortunately, we did not plan to use a structured
assessment of the implementation Using a framework like
RE-AIM would have strengthened the study [46]. Future
studies may benefit from using such frameworks. The set-
ting and variety of units makes the results generalizable and
possible to compare across nursing homes in Norway and
comparable countries.
Conclusion
The medication review with collegial mentoring was im-
plemented and well received in all units based on system-
atic assessments of patients for pain, neuropsychiatric
symptoms, and health. Collegial mentoring was perceived
as positive and valuable, and learning from each other was
found to facilitate decision-making pertaining to difficult
aspects of medication prescription. Knowledge about bar-
riers and promotors can enhance the implementation of
similar interventions.
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